A Master Protocol for Randomized, Controlled, Phase 2 Clinical Trials of Multiple Interventions for the Treatment of Adults with Moderate-to-Severe Atopic Dermatitis Register Today!
Atopic Dermatitis – J4E-MC-IMMB (ISA FR01)
Read More
Obesity and Cardiovascular Disease – J1I-MC-GZBM
A Randomized, Double-Blind, Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once Weekly Compared to Placebo in Participants with Severe Obesity and Established Cardiovascular Disease (TRIUMPH-3) Register Today!
Osteoarthritis of the knee – J1I-MC-GZBN
A Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants who have Obesity or Overweight and Osteoarthritis of the Knee: A Randomized, Double-Blind, Placebo-Controlled Trial (TRIUMPH-4) Register Today!
Moderna -mRNA-1283-P301 – COVID-19 vaccine booster
A randomized, observer-blind, active-controlled Phase 3 study to investigate the safety, immunogenicity, and relative vaccine efficacy of mRNA-1283.222 administered as a booster dose compared with mRNA-1273.222 in participants aged 12 years and older for the prevention of COVID-19 Register Today!
Alopecia Areata – HZNP-DAX-201
A Phase 2A, Open Label, Proof-of-Concept Trial of Daxdilimab for the Treatment of Moderate-to-Severe Alopecia Areata Register Today!
Maternal-Infant Research on Environmental Chemicals (Mirec-Endo – Phase II)
A study to determine whether prenatal exposure to elevated levels of various environmental chemicals, as well as other in-utero factors are related to the onset and progression of puberty, child metabolic function and growth. Click here for more information. Register Today!
Clinical Research Coordinator
Caitlyn Van Zon
About Caitlyn We’ll tell you very soon!
Obesity – I8F-MC-GPIJ
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Tirzepatide on the Reduction of Morbidity and Mortality in Adults with Obesity Register Today!
Atopic Dermatitis – ACT17207
A Phase 2, randomized, double-blind, placebo controlled, multicenter proof-of-concept study evaluating efficacy and safety of rilzabrutinib in adult patients with moderate-to-severe atopic dermatitis who are inadequate responders or intolerant to topical corticosteroids. Register Today!